Purchase this article with an account.
R.A. P. De Carvalho, M. Taban, O. Kalous, P. Reynolds, N. Rao, A.L. Murphree; Eficacy of periocular carboplatin in a xenograft model of vitreous seeding human retinoblastoma. . Invest. Ophthalmol. Vis. Sci. 2004;45(13):5192.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To evaluate the efficacy of periocular carboplatin in a xenograft model of vitreous seeding retinoblastoma using a carboplatin–sensitive human cell line. Methods: To develop the vitreous seeding model of retinoblastoma, human tumor cells, previously shown in vitro to be sensitive to carboplatin (CHLA 203), were injected into the vitreous cavity of nude rats, unilaterally. To test the hypothesis that periocular injections are efficacious in treating intraocular retinoblastoma as previously published, 22 animals with vitreous seeding disease in one eye were randomized into 4 groups: placebo, carboplatin at doses of 200 ug, 500 ug, or 1 mg. The injections were administered twice a week for 4 weeks. Ophthalmoscopic evaluation was performed before and after treatment. Animals were euthanized 1 month after the last injection. Masked investigators graded the clinical and histopathological findings. Response to treatment was computed based on the scores before and after the injection for both clinical and histopathological findings. Frequency of complete and partial tumor regression was compared between groups using chi–square test. Simple and multiple linear regression models were applied to analyze the association between carboplatin doses and clinical, and histopathological findings after treatment. A type–I error smaller than 5% was adopted for statistical significance. Results: No animal responded to any of the concentrations of carboplatin and saline solution. Multiple and linear regression models did not demonstrate statistical significance of any association between dose of carboplatin and outcome variables (p > 0.1). Conclusions: Periocular carboplatin was not effective in this model using a carboplatin–sensitive cell line, in contradistinction to previously published results using transgenic models. In efficacy studies, xenograft models using human cell lines should be considered in addition to or as an alternative to transgenic models.
This PDF is available to Subscribers Only